1. Home
  2. BPMC vs CRL Comparison

BPMC vs CRL Comparison

Compare BPMC & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BPMC
  • CRL
  • Stock Information
  • Founded
  • BPMC 2008
  • CRL 1947
  • Country
  • BPMC United States
  • CRL United States
  • Employees
  • BPMC N/A
  • CRL N/A
  • Industry
  • BPMC Biotechnology: Pharmaceutical Preparations
  • CRL Biotechnology: Commercial Physical & Biological Resarch
  • Sector
  • BPMC Health Care
  • CRL Health Care
  • Exchange
  • BPMC Nasdaq
  • CRL Nasdaq
  • Market Cap
  • BPMC 8.3B
  • CRL 7.1B
  • IPO Year
  • BPMC 2015
  • CRL 2000
  • Fundamental
  • Price
  • BPMC N/A
  • CRL $176.91
  • Analyst Decision
  • BPMC Buy
  • CRL Buy
  • Analyst Count
  • BPMC 18
  • CRL 14
  • Target Price
  • BPMC $128.87
  • CRL $184.85
  • AVG Volume (30 Days)
  • BPMC 4.3M
  • CRL 807.2K
  • Earning Date
  • BPMC 07-31-2025
  • CRL 08-06-2025
  • Dividend Yield
  • BPMC N/A
  • CRL N/A
  • EPS Growth
  • BPMC N/A
  • CRL N/A
  • EPS
  • BPMC N/A
  • CRL N/A
  • Revenue
  • BPMC $562,121,000.00
  • CRL $4,022,597,000.00
  • Revenue This Year
  • BPMC $44.46
  • CRL N/A
  • Revenue Next Year
  • BPMC $32.78
  • CRL $2.49
  • P/E Ratio
  • BPMC N/A
  • CRL N/A
  • Revenue Growth
  • BPMC 99.19
  • CRL N/A
  • 52 Week Low
  • BPMC $73.04
  • CRL $91.86
  • 52 Week High
  • BPMC $129.65
  • CRL $254.15
  • Technical
  • Relative Strength Index (RSI)
  • BPMC 3.63
  • CRL 71.29
  • Support Level
  • BPMC $129.20
  • CRL $146.26
  • Resistance Level
  • BPMC $129.65
  • CRL $184.17
  • Average True Range (ATR)
  • BPMC 0.18
  • CRL 6.31
  • MACD
  • BPMC -16.40
  • CRL 1.63
  • Stochastic Oscillator
  • BPMC 0.00
  • CRL 80.84

About BPMC Blueprint Medicines Corporation

Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.

About CRL Charles River Laboratories International Inc.

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Share on Social Networks: